

UnitedHealthcare Community & State Pharmacy & Therapeutics Committee Minutes

September 8, 2011

Meeting Date: September 8, 2011

Location: Via conference call

Members in Attendance:

Members Absent:

Guests:



Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
Meeting called to order		5:09 PM		
I. Minutes of previous meetings	R. Brekosky	Minutes of June 2011 UnitedHealthcare Community & State P&T meeting were reviewed.	Minutes reviewed, approved	15:0
II. New Formulations	A. Hindman	1) Androgel 1.62% (testosterone) Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	14:0
	A. Hindman	2) Creon 3000 unit (pancrelipase) Recommendation: Categorize as Essential Class, add as preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	13:0
	A. Hindman	3) Duexis (ibuprofen/famotidine) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	14:0
	A. Hindman	4) Lazanda (fentanyl nasal spray) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	14:0
	A. Hindman	5) Oxecta (oxycodone HCl) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	D. Morgan	6) Gamunex-C (immune globulin injection (human) 10%) Recommendation: Categorize as Medical Benefit	Motion made, seconded, and carried to accept recommendation	15:0
	D. Morgan	7) Lupron Depot 6 Month (leuprolide acetate for depot suspension) Recommendation: Categorize as Essential Class, add as preferred with prior authorization (PA) on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	D. Morgan	8) Sylatron (peginterferon alfa-2b) subcutaneous injection Recommendation: Categorize as Essential Drug, add as preferred with prior authorization (PA) on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
III. New Drugs	A. Hindman	1) Arcapta Neohaler (indacaterol) Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	2) Difidac (fidaxomicin) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	3) Edurant (rilpivirine) Recommendation: Categorize as Essential Class, add as preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	4) Complera (emtricitabine/rilpivirine/tenofovir) Recommendation: Categorize as Essential Class, add as preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	14:0

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
	D. Morgan	5) Incivek (telaprevir)	Motion made, seconded, and carried to accept recommendation	15:0
III. New Drugs CONT'D		Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs		
	D. Morgan	6) Victrelis (boceprevir) Recommendation: Categorize as Essential Class, add as preferred with prior authorization (PA) on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	7) Potiga (exogabine) Recommendation: Categorize as Essential Class, add as preferred with step therapy (ST) on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	8) Tradjenta (linagliptin) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	9) Xarelto (rivaroxaban) Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	10) Zytiga (abiraterone) Recommendation: Categorize as Essential Class, add as preferred with prior authorization (PA) on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
IV. Class Reviews	A. Hindman	1) Anticonvulsants Recommendation: Confirm class review Recommendation: Remove step therapy requirement from levetiracetam and oxcarbazepine Recommendation: Implement age edit of 10 years of age on levetiracetam and oxcarbazepine oral liquid formulations. Current users will be grandfathered.	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	2) Statins - Follow Up Recommendation: Confirm follow up	Motion made, seconded, and carried to accept recommendation	15:0
V. PDL Additions/Deletions/ Modifications	A. Hindman	1) Mepron (atovaquone) Recommendation: Implement prior authorization. Current users will be grandfathered.	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	2) Citalopram 40 mg Recommendation: Change quantity limit to one tablet per day. Current users of doses greater than 40 mg per day will be grandfathered.	Motion made, seconded, and carried to accept recommendation	15:0
	R. Brekosky	3) MASS SCO Plan Additions Recommendation: add Sarna lotion to MASS SCO plan PDL Recommendation: add fexofenadine OTC to MASS SCO plan PDL	Motion made, seconded, and carried to accept recommendation	15:0
VI. Clinical Guidelines	D. Morgan	1) Incivek (telaprevir)_Victrelis (boceprevir)	Motion made, seconded, and carried to accept recommendation	15:0
	D. Morgan	2) Sylatron (peginterferon alfa-2b)	Motion made, seconded, and carried to accept recommendation	15:0
	S. Mulder	3) Mepron (atovaquone)	Motion made, seconded, and carried to accept recommendation	15:0
	J. Hackett	4) Gilenya (fingolimod)	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	5) Potiga (exogabine)	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	6) Xarelto (rivaroxaban)	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	7) Difucid (fidaxomicin)	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	8) Gabitril (tiagabine)_Vimpat (lacosamide)	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	9) Oral Chemotherapy	Motion made, seconded, and carried to accept recommendation	15:0

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
	D. Morgan	10) Lupron (leuprolide acetate)	Motion made, seconded, and carried to accept recommendation	15:0
	D. Morgan	11) Erythroid Stimulants	Motion made, seconded, and carried to accept recommendation	15:0
VII. Annual Review	A. Hindman	1) Clinical Guidelines Recommendation: Confirm annual review of all clinical guidelines.	Motion made, seconded, and carried to accept recommendation	15:0
VIII. Quality Monitoring	R. Brekosky L. Cormier J. Hackett J. Hackett C. Shaw A. Hindman	1) The Quality Management Reports for the 2nd quarter of 2011 were reviewed 2) The DUR Board Summary Report for June 2011 was reviewed 3) Top 25 drugs by cost and volume for the 2nd quarter of 2011 were reviewed 4) Top 10 drugs requested - approvals and denials for the 2nd quarter of 2011 were reviewed 5) The grievance and appeals statistics for the 2nd quarter of 2011 were reviewed 6) The IRR results for the 3rd quarter of 2011 were reviewed	Motion made, seconded, and carried to accept recommendation	15:0
Adjournment		6:45 PM		
<p>Votes not totaling 15 are the result of abstentions.</p> <p>NOTE: Actions documented in these minutes document what transpired at the meeting and do not serve as notice of formulary/PDL change. All formulary/PDL changes must be approved by the Department of Public Welfare. Formulary/PDL changes are only official once approved and subsequently posted/distributed in a change notice.</p>				